Drug intelligence / Profile preview

camizestrant + saruparib

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

Camizestrant + saruparib is an investigational combination therapy being developed for hormone receptor-positive (HR+), HER2-negative advanced breast cancer. Camizestrant is an orally bioavailable, next-generation selective estrogen receptor degrader (SERD) and complete estrogen receptor (ER) antagonist with activity in both ESR1 mutant and wild type settings. Saruparib (AZD5305) is a potent and selective inhibitor of PARP1 with minimal effect on PARP2. This combination is being evaluated in clinical trials, particularly for patients with BRCA1, BRCA2, or PALB2 mutations.

Other names: saruparib + camizestrant

Targets

PARP1 (Poly (adp-ribose) polymerase 1)ESR1 (ERα)

Beyond the preview

Go deeper on camizestrant + saruparib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on camizestrant + saruparib.

Explore the full profile